ESSA Pharma Inc
NASDAQ:EPIX
Relative Value
There is not enough data to reliably calculate the relative value of EPIX.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
EPIX Competitors Multiples
ESSA Pharma Inc Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
CA |
ESSA Pharma Inc
NASDAQ:EPIX
|
270.3m USD | 0 | -10.5 | -4 | -4 | ||
US |
Abbvie Inc
NYSE:ABBV
|
286.7B USD | 5.3 | 59.5 | 12.9 | 19.7 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
144.8B USD | 5.1 | 21.6 | 16.1 | 24.1 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
102.5B USD | 10.4 | 28.3 | 22.6 | 23.7 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
96.9B USD | 7.4 | 24.5 | 16.2 | 17.8 | ||
AU |
CSL Ltd
ASX:CSL
|
132B AUD | 6.1 | 34.9 | 21.2 | 26.2 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
81.6B USD | 3 | 14.4 | 7.9 | 10.2 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
41.2B USD | 6 | -8.7 | -9.2 | -7.8 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
29.9B USD | 3 | 25.8 | 14 | 17.4 | ||
KR |
Celltrion Inc
KRX:068270
|
36.6T KRW | 16.8 | 68.3 | 41.9 | 57.7 |